Back to UBS Group AG UBS Group AG

CTMXCTMX
Showing 8 of 30 quarters

Position history for UBS Group AGUBS Group AG's holdings in CYTOMX THERAPEUTICS INC.

UBS Group AG holds 3.5M shares of CTMX (CYTOMX THERAPEUTICS INC.), worth $13M as of 2026-Q2. The position was increased (+11.2% shares). CTMX represents 0.0% of UBS Group AG's portfolio.

Current Value

$13M

Current Shares

3.5M

Total Value Change

+$12.9M

Total Shares Change

+3.4M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
3.5M
+11.2%
$13M0.0%$3.75
31
2026-Q1
Increased
3.1M
+741.6%
$14.7M0.0%$4.81
45
2025-Q4
Increased
370,739
+1128.9%
$1.6M0.0%$4.16
41
2025-Q3
Decreased
30,168
-92.6%
$96,2360.0%$3.23
0
2025-Q2
Decreased
408,035
-45.4%
$926,2390.0%$2.25
0
2025-Q1
Increased
746,788
+46.8%
$474,9570.0%$0.63
33
2024-Q4
Increased
508,556
+635.6%
$523,8120.0%$1.02
39
2024-Q3
Decreased
69,135
-1.8%
$81,5790.0%$1.20
0

Other major holders of CTMX: FMR LLC, BlackRock, Inc., BNP PARIBAS FINANCIAL MARKETS

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used